Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
Trial details
- Registry ID
- NCT07443202
- Phase
- Phase 2
The FDA approved lotilaner on 24 Jul 2023.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)NCT07443202 | TARS | Phase 2 | Enrolling by invitation | 2026-12-31Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-07-24Day | lotilaner | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA217603", "applicant_as_listed_by_fda": "TARSUS", "brand_names": ["XDEMVY"], "active_ingredients": ["LOTILANER"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230724", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |